Absci Corporation a data-first generative AI drug creation company, and Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, unveiled a collaboration to design a novel therapeutic using generative AI.
“Bringing together two leaders in biotechnology innovation represents an opportunity to accelerate pharmaceutical R&D,” said Absci Founder & CEO Sean McClain. “We are excited to strengthen our relationship with Twist and leverage the power of our shared platforms to bring better biologics to patients faster.”
Through this new collaboration, Absci and Twist will design a novel therapeutic candidate against an undisclosed target using Absci’s advanced generative AI platform and Twist’s synthetic DNA platform. The program will leverage Absci’s AI de novo design capabilities and Twist’s silicon-based synthesis platform, including its Multiplexed Gene Fragments for the testing and validation of antibody candidates designed using Absci’s generative AI technology platform. Twist and Absci intend to seek a partner for human clinical development and commercialization.
Also Read: Tempus Announces Collaboration With JW Pharmaceutical
“We have been working with Absci for several years and look forward to extending our collaboration beyond a preferred supplier to leverage their AI platform along with Twist’s capabilities to discover antibodies to a key biological target that potentially impacts multiple disease areas,” said Emily M. Leproust, Ph.D., CEO and cofounder of Twist Bioscience.
This program adds to Absci’s growing portfolio of collaboration programs with industry-leading pharmaceutical companies such as AstraZeneca and Merck, as well as with leading academic institutes such as Memorial Sloan Kettering Cancer Center. In addition to its partnered programs, Absci continues to advance an internal pipeline of multiple drug candidates.
For this program, Twist will apply products from its SynBio portfolio developed for antibody discovery including Multiplexed Gene Fragments, Express portfolio and synthesis of long DNA. This partnership illustrates the value of Twist’s platform from individual pieces of DNA all the way through antibody discovery.
SOURCE: GlobeNewswire